PeptideScanner
U.S. label record↗Metabolic↗

Pramlintide↗

Related names in cited records: SymlinPen↗

An amylin analogue. This profile cites a U.S. label record.↗

Citation markers ↗ open the public records supporting the adjacent statements.

Profile update · July 27, 2026

We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change. 1

This version supersedes public version 1.

Start here

The evidence at a glance

What is its status in the cited records?

U.S. label record. The cited DailyMed label identifies Pramlintide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗

Status sources checked through July 22, 2026. See status sources and coverage →

What do the reviewed human studies say?

Human evidence reviewed September 15, 2026 · Review version 1.

Review source snapshots checked September 15, 2026 · Integrity checked September 15, 2026.

Three selected reports examine pramlintide alongside insulin in diabetes. Two are year-long adjunctive-treatment trials; the third evaluates an experimental automated insulin-and-pramlintide system and is not interchangeable with routine labeled treatment.↗↗↗

What the reviewed sources report

Year-long trials reported modest HbA1c and weight changes compared with placebo added to insulin. Nausea was common. The automated-delivery study met its glucose-control noninferiority objective but did not improve its emotional-burden endpoint.↗↗↗

What remains unresolved?

  • What do the current label and complete trial reports establish about severe hypoglycemia and discontinuation?↗↗↗
  • Can longer studies reproduce the automated-delivery findings and assess patient-important outcomes?↗↗↗

Read study designs, results, limitations, and sources →

What does the U.S. product label say?

Symlin · Read September 15, 2026 · Preserved label summary 1

Which population and use does the label cover?

The cited label describes adjunctive use with mealtime insulin in type 1 or type 2 diabetes when desired glucose control has not been achieved despite optimal insulin therapy. Pediatric safety and effectiveness have not been established. Label: 1, 8.4 ↗

Which safety limits matter?

The boxed warning concerns severe hypoglycemia when used with insulin, particularly in type 1 diabetes. Contraindications include hypoglycemia unawareness, confirmed gastroparesis and serious hypersensitivity. A study reporting no overall increase in severe events does not cancel the label warning. Label: 1, 4, 5, 8.4, boxed warning ↗

Label edition and source pins

U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.

SYMLINPEN (pramlintide acetate) injection · SPL version 18 · published 2024-08-20

Label ZIP SHA-256: 41e40e12d2e7bbf400a8bcd1a8032e423aa305f795982acb1264301692a93a15. Extracted XML SHA-256: e223f4cb25daee6d6785fc4e0d427c65dbbe94d27da19f34b5fafb7ba6a1842a.

Open versioned label context data →

Reviews summarize selected studies; their scope and limitations are shown above.

Research coverage and study families

Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.

Open machine-readable coverage and record decisions →

PubMed search

Identity/name search without publication-type filtering; primary human reports, extensions, combinations and other reports require separate eligibility decisions. Known selected reports were recovered.

450 retrieved · 3 included · 0 excluded · 447 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

"pramlintide"[Title/Abstract] OR "Symlin"[Title/Abstract]

  • Full-text appraisal and screening of unassessed records remain open.
  • Registry comparison, additional aliases and references, and regulator reconciliation require separate checks.

Showing 25 of 450 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. PubMed 38906614 — include: Selected human report; abstract and record metadata reviewed. Study families: NCT04163874.
  2. PubMed 15498087 — include: Selected human report; abstract and record metadata reviewed. Study families: pramlintide-PMID15498087-registry-linkage-unresolved.
  3. PubMed 12610038 — include: Selected human report; abstract and record metadata reviewed. Study families: pramlintide-PMID12610038-registry-linkage-unresolved.
  4. PubMed 41207308 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  5. PubMed 42695140 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  6. PubMed 42452898 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  7. PubMed 41850952 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  8. PubMed 41702251 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  9. PubMed 30000033 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  10. PubMed 41661442 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  11. PubMed 41747885 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  12. PubMed 41344603 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  13. PubMed 41167578 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  14. PubMed 41708975 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  15. PubMed 41549439 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  16. PubMed 40838347 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  17. PubMed 25905364 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  18. PubMed 41022243 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  19. PubMed 41174925 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  20. PubMed 40618954 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  21. PubMed 40513482 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  22. PubMed 40360789 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  23. PubMed 40169506 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  24. PubMed 40332747 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  25. PubMed 39998445 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.

FDA search

Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.

1 retrieved · 1 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

products.active_ingredients.name:"PRAMLINTIDE"

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:10:25.116489+00:00 · HTTP 200 · SHA-256 08b982de41e616563b21c17a9da8cfde8c0ad2e96d881bb8774eb26e2541a222.

  • Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
  • This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.

Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. FDA NDA021332 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: PRAMLINTIDE ACETATE.

EMA search

Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.

0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

Case-insensitive word-boundary identity terms: ["Pramlintide", "SymlinPen"]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:34:22.905972+00:00 · HTTP 200 · SHA-256 a947c2b8a56ac2b92ec96156843f262f5e516f83b375d6791d67a8f6dc695729.

  • Document appraisal and national European sources remain open.
  • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    EMA search

    Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.

    0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

    Search terms, record decisions and remaining work

    Case-insensitive word-boundary identity terms: ["Pramlintide", "SymlinPen"]

    Source retrievals and payload pins
    • Open the source endpoint ↗

      Retrieved 2026-09-15T08:34:29.167460+00:00 · HTTP 200 · SHA-256 c0c68d7d77783e0355cbc75bdd04772e9acc163236fc68abcd794477c4c3d439.

    • Document appraisal and national European sources remain open.
    • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

    Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

      EMA search

      Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.

      0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

      Search terms, record decisions and remaining work

      Case-insensitive word-boundary identity terms: ["Pramlintide", "SymlinPen"]

      Source retrievals and payload pins
      • Open the source endpoint ↗

        Retrieved 2026-09-15T08:34:31.262344+00:00 · HTTP 200 · SHA-256 7448bf4e77e3345b3f3fbb7062c335d2302d8ea458a246bbe8256ce48aad2806.

      • Document appraisal and national European sources remain open.
      • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

      Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

        ClinicalTrials.gov search

        ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.

        66 retrieved · 0 included · 0 excluded · 66 awaiting a decision · 0 full-text appraisals

        Search terms, record decisions and remaining work

        "Pramlintide" OR "SymlinPen"

        Source retrievals and payload pins
        • Open the source endpoint ↗

          Retrieved 2026-09-15T11:26:49.745337+00:00 · HTTP 200 · SHA-256 be767b537048aaf484f06333f8ff1eafee28e35f7713ab75c70b230b6931f5c3.

        • Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
        • Other registries, unregistered studies and additional aliases remain outside this query.

        Showing 25 of 66 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

        1. ClinicalTrials.gov NCT00442767 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        2. ClinicalTrials.gov NCT00673387 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        3. ClinicalTrials.gov NCT03512236 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        4. ClinicalTrials.gov NCT00690235 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        5. ClinicalTrials.gov NCT01269008 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        6. ClinicalTrials.gov NCT00950677 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        7. ClinicalTrials.gov NCT00732147 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        8. ClinicalTrials.gov NCT00819234 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        9. ClinicalTrials.gov NCT04972175 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        10. ClinicalTrials.gov NCT05199714 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        11. ClinicalTrials.gov NCT01708044 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        12. ClinicalTrials.gov NCT06186063 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        13. ClinicalTrials.gov NCT00229658 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        14. ClinicalTrials.gov NCT00108004 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        15. ClinicalTrials.gov NCT00291772 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        16. ClinicalTrials.gov NCT02500979 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        17. ClinicalTrials.gov NCT03547427 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        18. ClinicalTrials.gov NCT01235741 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        19. ClinicalTrials.gov NCT07679516 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        20. ClinicalTrials.gov NCT03981627 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        21. ClinicalTrials.gov NCT00206297 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        22. ClinicalTrials.gov NCT04163874 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        23. ClinicalTrials.gov NCT04074317 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        24. ClinicalTrials.gov NCT00313183 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        25. ClinicalTrials.gov NCT00042471 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        Read the full Human Evidence Review

        Supervised synthesis

        What do selected human studies report about Pramlintide?

        Manually reviewed September 15, 2026 · version 1

        Browse all Human Evidence Reviews · Open preserved synthesis version 1 →

        Three selected reports examine pramlintide alongside insulin in diabetes. Two are year-long adjunctive-treatment trials; the third evaluates an experimental automated insulin-and-pramlintide system and is not interchangeable with routine labeled treatment.123

        Bottom line from this bounded source set

        Year-long trials reported modest HbA1c and weight changes compared with placebo added to insulin. Nausea was common. The automated-delivery study met its glucose-control noninferiority objective but did not improve its emotional-burden endpoint.123

        Reviewed study record

        Type 1 diabetes: year-long adjunctive trial

        Design

        Randomized, double-blind, placebo-controlled trial over 52 weeks alongside insulin.1

        Population

        651 people with type 1 diabetes participated.1

        Outcomes reported

        The reported active groups had HbA1c reductions of 0.29–0.34 percentage points versus 0.04 with placebo. Weight declined by 0.4 kg versus a 0.8 kg increase. Transient nausea was the most common adverse event.1

        Limitations

        HbA1c and body weight are distinct from long-term complication outcomes. The abstract does not replace the full hypoglycemia analysis or label warnings.1

        Reviewed study record

        Type 2 diabetes: year-long adjunctive trial

        Design

        Randomized, double-blind, placebo-controlled trial over 52 weeks in insulin-treated patients.2

        Population

        656 people with type 2 diabetes participated.2

        Outcomes reported

        One active group had a 0.62 percentage-point HbA1c reduction at week 52 and weight change of −1.4 kg versus +0.7 kg with placebo. The authors reported no overall increase in severe-hypoglycemia rate; nausea was common.2

        Limitations

        A trial-wide hypoglycemia result does not negate regimen-specific risk or current boxed warnings. The report concerns selected insulin-treated patients.2

        Reviewed study record

        Experimental automated delivery

        Design

        Randomized crossover comparison of three automated-delivery approaches, each studied for 14 days.3

        Population

        32 participants enrolled; 30 completing all interventions were analyzed, including 15 adults and 15 adolescents.3

        Outcomes reported

        The insulin-and-pramlintide system with simple meal announcements met the prespecified glucose-control noninferiority comparison but did not improve emotional burden. Gastrointestinal symptoms occurred more often with pramlintide; no serious adverse events occurred.3

        Limitations

        The small, short crossover trial excluded noncompleters from the primary analysis. It evaluates a combined device-and-drug approach and cannot establish longer-term safety or a broader approved indication.3

        Reviewed source set

        1. PubMed · 15498087Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. ↗PubMed PMID 15498087 · EFetch XML reviewed 2026-09-15 · payload SHA-256 c0f7cc8a6cbcc81776a4ab5b35e375bce4952288aed03e499b891ad93ccdb2e7
          No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1111/j.1464-5491.2004.01319.x. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
        2. PubMed · 12610038Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. ↗PubMed PMID 12610038 · EFetch XML reviewed 2026-09-15 · payload SHA-256 a89b90837191319cce0d50ea4f2bda1b830e012141308b8b84e4893223694d13
          No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.2337/diacare.26.3.784. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
        3. PubMed · 38906614Simple meal announcements and pramlintide delivery versus carbohydrate counting in type 1 diabetes with automated fast-acting insulin aspart delivery: a randomised crossover trial in Montreal, Canada. ↗PubMed PMID 38906614 · EFetch XML reviewed 2026-09-15 · payload SHA-256 41d8294d068021181ac91c0e24653b6ad9cd594c0d216c1ab732b5e6f7334c8a
          No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/s2589-7500(24)00092-x. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
        Explore status sources, recent additions, and coverage gaps

        Living status brief

        What is the current status of Pramlintide?

        U.S. label record. The cited DailyMed label identifies Pramlintide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗

        The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.

        67Dated records48PubMed records5Trial records14Regulatory records

        Evidence present

        What records are connected here?

        Evidence lanes
        3
        Source years
        15
        Drugs@FDA applications
        1

        These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

        Latest source-dated record

        What changed most recently at a cited source?

        Literature metadata · source date July 11, 2026

        PubMed record PMID 41022243↗Added to PeptideScanner August 12, 2026

        Coverage gaps

        What remains unknown or unsupported?

        PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

        PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

        Open the complete timeline →Browse all connected recordsFollow via RSS
        Explore the Evidence Map and record counts

        Evidence Map v1

        What kinds of records connect to Pramlintide?

        Compare collection coverage →

        This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

        67Selected dated records
        68Connected citations
        15Populated source years2001–2026
        3/4Record lanes present
        Clinical trials5Open matching records →Literature metadata48Open matching records →Regulatory14Open matching records →Safety0No selected dated records

        Registered human studies

        Trial composition

        2 of 5 selected trial records include at least one phase value; 2 of 5 include a status value in the retained structured contract.

        19 public history versions connect to 4 of these trial records across 11 submitted years. Open the record-history collection →

        PhasesNot applicable 1Phase 3 1
        Status at observationCompleted 2

        A phase value is unavailable here for 3 selected records; this is not counted as “no phase.”

        A status value is unavailable here for 3 selected records; this is not counted as a trial status.

        PubMed bibliography

        Publication composition

        24 of 48 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

        Publication typesJournal Article 24Research Support, Non-U.S. Gov't 8Randomized Controlled Trial 4Review 3Clinical Trial 2Comment 1Comparative Study 1Multicenter Study 1Research Support, N.I.H., Extramural 1

        Bibliography fields unavailable here for 24 selected records; the records remain visible as metadata observations.

        Regulatory and publication surfaces

        What is structurally connected?

        Drugs@FDA applications
        1
        FDA Federal Register documents
        2
        DailyMed SPL versions
        11
        Canonical profile
        Published
        Profile structured data
        Published
        Linked dated records
        67

        Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

        Profile publication history and record counts

        Research hub

        Explore the Pramlintide evidence record

        Open all 67 records →
        67Dated records
        3Evidence types
        67Cited public sources
        15Source years

        Change ledger

        Recently changed for Pramlintide

        Open all 68 events →

        PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

        Record added

        ClinicalTrials.gov record NCT00206297

        PeptideScanner retained ClinicalTrials.gov record NCT00206297 at 2026-07-30T21:36:16.909Z. Its registry update date was 2016-07-14, and PeptideScanner's reviewed identity mapping was pramlintide.

        PeptideScanner change date
        September 9, 2026
        Cited source date
        July 14, 2016
        Evidence lane
        Clinical trials
        Open the cited record →
        Cited source
        Record added

        Pramlintide DailyMed SPL version 1

        DailyMed lists Structured Product Labeling version 1 for the reviewed Pramlintide label family with a published date of 2015-01-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

        PeptideScanner change date
        August 22, 2026
        Cited source date
        January 8, 2015
        Evidence lane
        Regulatory
        Open the cited record →
        Cited source
        Record added

        Pramlintide DailyMed SPL version 11

        DailyMed lists Structured Product Labeling version 11 for the reviewed Pramlintide label family with a published date of 2018-11-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

        PeptideScanner change date
        August 22, 2026
        Cited source date
        November 14, 2018
        Evidence lane
        Regulatory
        Open the cited record →
        Cited source

        Official-source collections

        Source records for Pramlintide

        Open the full research atlas →
        PubMed48

        24 with attributed title, venue, publication-date, and type metadata.

        Journal Article (24)Research Support, Non-U.S. Gov't (8)Randomized Controlled Trial (4)
        1. Simple meal announcements and pramlintide delivery versus carbohydrate counting in type 1 diabetes with automated fast-acting insulin aspart delivery: a randomised crossover trial in Montreal, Canada.The Lancet. Digital health · 2024 Jul
        2. Development and validation of a new robust RP-HPLC method for simultaneous quantitation of insulin and pramlintide in non-invasive and smart glucose-responsive microparticles.Research in pharmaceutical sciences · 2022 10 29
        3. Physico-chemical properties of co-formulated fast-acting insulin with pramlintide.International journal of pharmaceutics · 2018 06 19
        Explore all selected literature →
        ClinicalTrials.gov5

        19 public history versions across these dated registry records; status labels apply only to each cited observation.

        Recruiting history (8)Completed history (6)Active Not Recruiting history (3)
        Completed at observation (5)
        Type 1 Diabetes (2)Not applicable (1)Phase 3 (1)Completed (2)
        Pramlintide · Drug (2)
        1. NCT05199714Registry update October 25, 2023 · completed at observation
        2. NCT01841359Registry update June 29, 2023 · completed at observation
        3. NCT00690235Registry update November 16, 2018 · completed at observation
        Explore all selected trial records →Explore all public record history →
        DailyMed SPL history11

        Version metadata and exact historical ZIP receipts for the reviewed label family, without reproducing or interpreting label text.

        1. SPL version 18Published 2024-08-20 · ZIP SHA-256 41e40e12d2e7…
        2. SPL version 17Published 2024-07-09 · ZIP SHA-256 10eeb5c9c379…
        3. SPL version 16Published 2024-04-15 · ZIP SHA-256 fa9d9a60eebb…
        4. SPL version 14Published 2023-02-23 · ZIP SHA-256 7d6fd51c4f94…
        5. SPL version 13Published 2022-10-21 · ZIP SHA-256 d852564b92b0…
        Explore all DailyMed label versions →

        Counts and links describe PeptideScanner’s selected records. They are not rankings and do not establish research quality, safety, effectiveness, or medical relevance.

        Evidence types

        Coverage by source year

        Selected records span June 8, 2001 to July 11, 2026.

        Continue exploring

        Profiles with overlapping source-year coverage

        Open the research atlas →

        These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

        Leuprolide14 shared source years215 dated records · 4 evidence typesOctreotide14 shared source years160 dated records · 4 evidence typesTeriparatide14 shared source years149 dated records · 3 evidence typesExenatide14 shared source years119 dated records · 3 evidence types

        These dates come from selected source records and PubMed metadata. They are not a complete or continuous timeline of research, safety, approval, or effectiveness.

        Evidence summary

        What the cited records say

        The cited DailyMed label identifies Pramlintide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗

        This is a source summary, not a medical recommendation. Status may differ by jurisdiction and product.

        Cited context

        Related records

        Organizations named in cited records

        • U.S. National Library of Medicine↗

        Dated source history

        Updates connected to this profile

        Open the full cross-source timeline →

        1. Literature metadata

          PubMed record PMID 41022243↗

          PeptideScanner retained PubMed bibliographic metadata for PMID 41022243 at 2026-08-10T18:13:37.942Z. PubMed recorded a metadata revision date of 2026-07-11 and an Entrez history date of 2025-09-29. PeptideScanner associated this retained record with the identity slug pramlintide. These dates describe PubMed metadata history, not the article's original publication date.↗

        2. Literature metadata

          PubMed record PMID 41174925↗

          PeptideScanner retained PubMed bibliographic metadata for PMID 41174925 at 2026-08-10T18:13:37.974Z. PubMed recorded a metadata revision date of 2026-07-05 and an Entrez history date of 2025-11-01. PeptideScanner associated this retained record with the identity slug pramlintide. These dates describe PubMed metadata history, not the article's original publication date.↗

        3. Literature metadata

          PubMed record PMID 39109464↗

          PeptideScanner retained PubMed bibliographic metadata for PMID 39109464 at 2026-07-30T16:14:08.819Z. PubMed recorded a metadata revision date of 2026-06-04 and an Entrez history date of 2024-08-07. PeptideScanner associated this retained record with the identity slug pramlintide. These dates describe PubMed metadata history, not the article's original publication date.↗

        4. Literature metadata

          Adjunctive therapy with pramlintide in patients with type 1 or type 2 diabetes mellitus.↗

          PubMed lists PMID 17064208 in Pharmacotherapy as Journal Article, Review, with publication-date metadata of 2006-11 (month precision). PeptideScanner associated the retained record with the identity slug pramlintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

        5. Literature metadata

          Assessing treatment satisfaction in patients treated with pramlintide as an adjunct to insulin therapy.↗

          PubMed lists PMID 17624233 in Current medical research and opinion as Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2007-08 (month precision). PeptideScanner associated the retained record with the identity slug pramlintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

        6. Literature metadata

          Clinical experience with the addition of pramlintide in patients with insulin-requiring type 2 diabetes.↗

          PubMed lists PMID 17909093 in Diabetes care as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2007-10-01 (day precision). PeptideScanner associated the retained record with the identity slug pramlintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

        7. Literature metadata

          Continuous subcutaneous pramlintide infusion therapy in patients with type 1 diabetes: observations from a pilot study.↗

          PubMed lists PMID 19546056 in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists as Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009 Nov-Dec (source-text precision). PeptideScanner associated the retained record with the identity slug pramlintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

        8. Literature metadata

          A pilot trial of pramlintide home usage in adolescents with type 1 diabetes.↗

          PubMed lists PMID 19858155 in Pediatrics as Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, with publication-date metadata of 2009-10-26 (day precision). PeptideScanner associated the retained record with the identity slug pramlintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

        9. Literature metadata

          Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes.↗

          PubMed lists PMID 19502544 in Diabetes care as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009-06-05 (day precision). PeptideScanner associated the retained record with the identity slug pramlintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

        10. Literature metadata

          Simple meal announcements and pramlintide delivery versus carbohydrate counting in type 1 diabetes with automated fast-acting insulin aspart delivery: a randomised crossover trial in Montreal, Canada.↗

          PubMed lists PMID 38906614 in The Lancet. Digital health as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-07 (month precision). PeptideScanner associated the retained record with the identity slug pramlintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

        11. Regulatory

          Pramlintide DailyMed SPL version 18↗

          DailyMed lists Structured Product Labeling version 18 for the reviewed Pramlintide label family with a published date of 2024-08-20. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗

        12. Regulatory

          Pramlintide DailyMed SPL version 17↗

          DailyMed lists Structured Product Labeling version 17 for the reviewed Pramlintide label family with a published date of 2024-07-09. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗

        Public beta · Selective source coverageNot medical advice · No dosing or purchasing guidance